New Antibody-Drug conjugate enters early human trials for advanced cancers

NCT ID NCT07644650

Not yet recruiting Disease control Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MST-168 (an antibody-drug conjugate)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have specific targets.
What could go wrong: This is an early Phase 1 trial, so safety and dosing are still being figured out. It may not work or could have side effects, and it's only for certain tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLAMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLAMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.